Charles River Laboratories   2Q Revenues: $292.9 million (+3%) 2Q Earnings: $27.7 million (-9%) YTD Revenues: $584.2 million (+2%) YTD Earnings: $53.5 million (-6%) Comments: Research Models and Services (RMS) revenues were $179.0 million in the quarter, up 3% driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) sales were $114.0 million, up 3% driven by increased sales ...